Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer
|
By LabMedica International staff writers Posted on 30 Aug 2015 |
|
An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer.
The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed by MDxHealth SA (Herstal, Belgium) and at the University Erasmus Medical Center (Rotterdam, The Netherlands). MDxHealth has now signed an exclusive worldwide biomarker license and scientific collaboration agreement with the University Erasmus Medical Center granting MDxHealth exclusive worldwide rights for the use of a number of its bladder cancer DNA methylation biomarkers for both laboratory tests as well as in vitro diagnostic (IVD) products. University Erasmus Medical Center will receive upfront and milestone payments and royalties on net sales on any commercialized products. The two organizations have also agreed to collaborate in the clinical development of this and future bladder cancer tests.
Current diagnostic tools for the detection of bladder cancer are invasive and, with a sensitivity limited to only about 70%, leave many patients at risk of having undetected cancer. The MDxHealth liquid biopsy was designed to rule-out bladder cancer in patients with hematuria (blood in urine) noninvasively. It is based on DNA biomarkers that become modified by cancer cells. The liquid biopsy identifies these modifications at the genetic level providing the physicians with a tool to aid in the diagnosis of cancer, assess the risk of recurrence or metastasis of the cancer, and predict an individual patient’s likely response to cancer treatment.
Preliminary data from clinical trials conducted by the partners is due to be reported at the September 9–11, 2015, 11th World Congress on Urological Research that will be held in Nijmegen (The Netherlands). A cohort of 154 patients with hematuria, were tested, and it was found that the liquid biopsy urine test for bladder cancer had a negative predictive value (NPV) of 98.3%.
Dr. Jan Groen, CEO of MDxHealth, said, "Critical to our strategy is the discovery and development of noninvasive tests for urological disease. These positive data lead us to be confident that we could launch a urine based, “liquid biopsy” testing solution that will provide physicians a cost-effective, patient-friendly test to accurately aid bladder cancer detection and recurrence monitoring. We are delighted to be working alongside University Erasmus Medical Center and look forward to initiating a larger evaluation study in bladder cancer patients in due course.”
Dr. Ellen Zwarthoff, a professor at University Erasmus Medical Center, said, “Bladder cancer is the fifth most common cancer in the western world, and will continue to cost many lives unless we identify new approaches to diagnose it early, at its most treatable stages.”
Related Links:
MDxHealth SA
University Erasmus Medical Center
The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed by MDxHealth SA (Herstal, Belgium) and at the University Erasmus Medical Center (Rotterdam, The Netherlands). MDxHealth has now signed an exclusive worldwide biomarker license and scientific collaboration agreement with the University Erasmus Medical Center granting MDxHealth exclusive worldwide rights for the use of a number of its bladder cancer DNA methylation biomarkers for both laboratory tests as well as in vitro diagnostic (IVD) products. University Erasmus Medical Center will receive upfront and milestone payments and royalties on net sales on any commercialized products. The two organizations have also agreed to collaborate in the clinical development of this and future bladder cancer tests.
Current diagnostic tools for the detection of bladder cancer are invasive and, with a sensitivity limited to only about 70%, leave many patients at risk of having undetected cancer. The MDxHealth liquid biopsy was designed to rule-out bladder cancer in patients with hematuria (blood in urine) noninvasively. It is based on DNA biomarkers that become modified by cancer cells. The liquid biopsy identifies these modifications at the genetic level providing the physicians with a tool to aid in the diagnosis of cancer, assess the risk of recurrence or metastasis of the cancer, and predict an individual patient’s likely response to cancer treatment.
Preliminary data from clinical trials conducted by the partners is due to be reported at the September 9–11, 2015, 11th World Congress on Urological Research that will be held in Nijmegen (The Netherlands). A cohort of 154 patients with hematuria, were tested, and it was found that the liquid biopsy urine test for bladder cancer had a negative predictive value (NPV) of 98.3%.
Dr. Jan Groen, CEO of MDxHealth, said, "Critical to our strategy is the discovery and development of noninvasive tests for urological disease. These positive data lead us to be confident that we could launch a urine based, “liquid biopsy” testing solution that will provide physicians a cost-effective, patient-friendly test to accurately aid bladder cancer detection and recurrence monitoring. We are delighted to be working alongside University Erasmus Medical Center and look forward to initiating a larger evaluation study in bladder cancer patients in due course.”
Dr. Ellen Zwarthoff, a professor at University Erasmus Medical Center, said, “Bladder cancer is the fifth most common cancer in the western world, and will continue to cost many lives unless we identify new approaches to diagnose it early, at its most treatable stages.”
Related Links:
MDxHealth SA
University Erasmus Medical Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
New
Gastrointestinal Panel
Xpert® GI Panel
Latest Industry News
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
- Sputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
- Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
- Unilabs Expands Digital Pathology Across European Network with Proscia Platform
- Digital Pathology Partnership Integrates Breast Cancer Diagnostic and Prognostic Tools
- MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
- Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
- Sepsis Diagnostics Market Growth Fueled by Faster Pathogen Detection Needs
- Project Advances Single-Cell Diagnostic Test for Triple-Negative Breast Cancer
- Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry
- Health Canada Licenses Point-of-Care Hematology Analyzer for Decentralized CBC Testing
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Microbiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
